CRESCENT BIOPHARMA, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CRESCENT BIOPHARMA, INC. (CBIO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$62.97 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-08.
Discontinued › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-08
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$62.97K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$438.57K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$225.38K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$22.98K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$704.20K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$268.59K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$212.60K.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$82.09K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$62.97K 10-Q · filed 2017-05-08 | -$501.54K derived: sum of 2 quarters · filed 2017-05-08 | -$726.92K derived: sum of 3 quarters · filed 2017-05-08 | -$749.90K derived: sum of 4 quarters · filed 2017-05-08 |
| 2016-12-31 | -$438.57K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$663.95K derived: sum of 2 quarters · filed 2017-03-01 | -$686.93K derived: sum of 3 quarters · filed 2017-03-01 | -$704.20K 10-K · filed 2017-03-01 |
| 2016-09-30 | -$225.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$248.37K derived: sum of 2 quarters · filed 2016-11-04 | -$265.63K 10-Q · filed 2016-11-04 | -$268.86K derived: sum of 4 quarters · filed 2017-05-08 |
| 2016-06-30 | -$22.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$40.25K 10-Q · filed 2016-08-04 | -$43.48K derived: sum of 3 quarters · filed 2017-05-08 | -$101.87K derived: sum of 4 quarters · filed 2017-05-08 |
| 2016-03-31 | -$17.27K 10-Q · filed 2017-05-08 | -$20.50K derived: sum of 2 quarters · filed 2017-05-08 | -$78.89K derived: sum of 3 quarters · filed 2017-05-08 | -$283.52K derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$3.23K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$61.62K derived: sum of 2 quarters · filed 2017-03-01 | -$266.25K derived: sum of 3 quarters · filed 2017-03-01 | -$268.59K 10-K · filed 2017-03-01 |
| 2015-09-30 | -$58.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$263.03K derived: sum of 2 quarters · filed 2016-11-04 | -$265.37K 10-Q · filed 2016-11-04 | -$280.23K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$204.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$206.97K 10-Q · filed 2016-08-04 | -$221.84K derived: sum of 3 quarters · filed 2017-03-01 | -$323.84K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$2.34K 10-Q · filed 2016-05-04 | -$17.20K derived: sum of 2 quarters · filed 2017-03-01 | -$119.20K derived: sum of 3 quarters · filed 2017-03-01 | -$201.02K derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$14.87K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$116.87K derived: sum of 2 quarters · filed 2017-03-01 | -$198.68K derived: sum of 3 quarters · filed 2017-03-01 | -$212.60K 10-K · filed 2017-03-01 |
| 2014-09-30 | -$102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$183.82K derived: sum of 2 quarters · filed 2015-11-12 | -$197.74K 10-Q · filed 2015-11-12 | -$210.17K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$81.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$95.74K 10-Q · filed 2015-08-06 | -$108.17K derived: sum of 3 quarters · filed 2016-02-29 | -$147.34K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$13.92K 10-Q · filed 2015-05-05 | -$26.35K derived: sum of 2 quarters · filed 2016-02-29 | -$65.52K derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | -$12.43K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$51.60K derived: sum of 2 quarters · filed 2016-02-29 | -$82.09K 10-K · filed 2016-02-29 | |
| 2013-09-30 | -$39.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$69.66K 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | -$30.49K 10-Q · filed 2014-07-31 | |||
| 2012-12-31 | -$326.18K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |